NCT07739901
Korean Real-world Study on MASLD/MASH Outcomes.
StatusActive, Not Recruiting
PhaseNot specified
SponsorNovo Nordisk A/S
Primary completion (estimated)
At risk: Primary completion moved at least 2 months later.
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 2 versions: 2 with changes below. See every version on ClinicalTrials.gov ↗
- Notable Eligibility criteria expanded, about 11 words
- Primary and study completion pushed from Sep 30, 2026 to Dec 28, 2026
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
Occurrence of decompensated cirrhosis
Timeframe: From index date (second VCTE and start of follow-up) to the first occurrence of major adverse liver outcome (MALO) (up to 31 Dec 2025)
Occurrence of hepatocellular carcinoma (HCC) confirmed by imaging or biopsy
Timeframe: From index date (second VCTE and start of follow-up) to the first occurrence of MALO (up to 31 Dec 2025)
Liver transplantation
Timeframe: From index date (second VCTE and start of follow-up) to the first occurrence of MALO (up to 31 Dec 2025)
All-cause death
Timeframe: From index date (second VCTE and start of follow-up) to the first occurrence of MALO (up to 31 Dec 2025)
Arms and interventions
cohort with MASLD/MASH
Adults with MASLD/MASH who had at least two VCTE-LSM assessments performed 1 to 5 years apart during routine clinical care. Medical records will be reviewed to assess the association between changes in VCTE-LSM risk tier and long-term clinical outcomes.
Other: No treatment is given
Sites
1 site in 1 country
- Novo Nordisk Investigational SiteSeoul, South Korea